On Thursday, BofA Securities updated its stance on Autodesk (NASDAQ:ADSK), raising the price target on the software company's shares to $325.00 from the previous $285.00 while keeping a Neutral rating. The adjustment comes after the analyst's extensive two-day engagement with customers and partners at Autodesk University.
The analyst reported that the general consensus among customers is a lack of plans to add new seats in the near term, despite strong backlogs, some at record levels. However, resource constraints were cited as a limiting factor for seat growth. Most customers attended the event with the intention to enhance their use of existing Autodesk products rather than expand their portfolios with new ones.
Discussions with partners indicated that demand for Autodesk's offerings remained relatively stable throughout the quarter. Nevertheless, a few partners observed a decrease in demand towards the end of the quarter, which they linked to caution ahead of the upcoming election.
Additionally, partners highlighted ongoing macroeconomic challenges in Europe, though these observations do not significantly diverge from recent results or the commentary provided by Autodesk's management.
The report reflects a detailed account of interactions and feedback gathered from various stakeholders within the Autodesk community. It provides insights into customer behavior and market sentiment without indicating any major shifts in the company's business trajectory. The new price target suggests a revised expectation for the stock's value, even as the overall outlook on the stock remains unchanged.
In other recent news, Autodesk reported a 2% increase in revenue and earnings per share of $2.15 for the second quarter, along with a free cash flow of $203 million. This comes alongside the successful transition to an agency model and the implementation of a direct customer billing transaction model in North America, leading to a projected 11% increase in its full-year 2025 revenue growth guidance.
Recent analyst notes from Oppenheimer, BMO Capital, and DA Davidson have maintained their respective ratings on Autodesk, with price targets ranging from $260 to $300. HSBC upgraded Autodesk from Hold to Buy, and Goldman Sachs shifted its stance from Sell to Neutral.
The company's strategic initiatives to modernize and gain market share in construction and manufacturing, as well as to enhance its artificial intelligence capabilities, were recognized by the analyst firms. Autodesk's progress towards achieving its fiscal year 2026 operating margin targets of 38-40% ahead of schedule in fiscal year 2025 was also highlighted.
These are the recent developments in Autodesk's strategic direction and financial performance.
InvestingPro Insights
Autodesk's financial metrics and market performance offer additional context to BofA Securities' analysis. According to InvestingPro data, Autodesk boasts a market capitalization of $62.45 billion and has demonstrated strong revenue growth, with an 11.38% increase in the last twelve months as of Q2 2025. This growth aligns with the stable demand reported by partners at Autodesk University.
The company's impressive gross profit margin of 91.92% underscores its operational efficiency, which could be a factor in maintaining its strong market position despite customers' hesitancy to add new seats. An InvestingPro Tip highlights that Autodesk has "impressive gross profit margins," further supporting this observation.
While BofA Securities maintains a Neutral rating, it's worth noting that Autodesk's stock is trading near its 52-week high, with a price that is 99.06% of its peak. This performance, coupled with the raised price target, suggests investor confidence in the company's prospects. However, another InvestingPro Tip cautions that the "RSI suggests the stock is in overbought territory," which investors may want to consider in light of the current valuation.
For those seeking a more comprehensive analysis, InvestingPro offers 17 additional tips on Autodesk, providing a deeper dive into the company's financial health and market position.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.